Aripiprazole, representing the first SGA that obtained approval for augmentation in MDD by the US Food and Drug Administration (Wang et al., 2016; Mohamed et al., 2017), stands out from most other SGAs as it exhibits a partial dopamine-2 (D2) receptor agonism, allowing the so-called “dopamine stabilization.” Together with its potency of partial agonism at the 5-HT1A receptor, these properties make aripiprazole particularly interesting for MDD treatment (Frankel and Schwartz, 2017). The gene discussed is HTR1A; the disease is major depressive disorder.